Like most websites The Medicine Maker uses cookies. In order to deliver a
personalized, responsive service and to improve the site, we remember and store information about how you use
it.
Learn more.
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
Stephen T. Colgan
The Power List 2016
Stephen T. Colgan
Senior Director, Global CMC, Pfizer Worldwide Research and Development
Dr. Colgan has advocated lean stability strategies for more than a decade. These strategies provide a focus on the highest risk attributes and time points and facilitate rapid introduction of medicines into clinical trials. Regulatory filings are more science and risk-based without impacting safety, efficacy, or quality of the product.